DOCSLIB.ORG

Agents on Reticuloruminal Hypomotility Induced by Xylazine in Cattle

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Agents on Reticuloruminal Hypomotility Induced by Xylazine in Cattle Antagonistic Effects of Alpha-adrenoceptor Blocking Agents on Reticuloruminal Hypomotility Induced by Xylazine in Cattle Y. Hikasa, K. Takase, S. Emi and S. Ogasawara* ABSTRACT ber les recepteurs adrenergiques a2, a Xylazine has been characterized as savoir: 0,5 mg/kg de tolazoline et 0,2 an agonist for a2-adrenoceptors (4-11). The intravenous injection of a mg/kg de yohimbine, annula linertie In fact, various actions of xylazine, e.g. standard dose (0.05 mg/kg) of xyla- du reseau et du rumen provoquee par sedation in mice and chickens (8), zine inhibited reticuloruminal motility la xylazine. La tolazoline s'avera plus analgesia in rats and mice (12), in cattle. Pretreatment with adreno- efficace que la yohimbine, puisque 0,5 inhibition of small intestinal motility in ceptor antagonists showing a2- mg/kg de yohimbine ne provoqua pas mice (13), hyperglycemia associated blocking activity, tolazoline (0.5 mg/ d'effet antagoniste et que 0,2 mg/kg de with inhibition of insulin release in kg) and yohimbine (0.2 mg/kg), yohimbine se revela moins efficace que cattle (14) and emesis in dogs (7), were antagonized the xylazine-induced 0,5 mg/kg de tolazoline. La prazosine, reported to be antagonized by agents reticuloruminal amotility. Tolazoline un antagoniste des recepteurs adrener- possessing a2-adrenoceptor blocking was more effective than yohimbine, giques al n'empecha pas linhibition de activity such as yohimbine, tolazoline, since an antagonistic effect was not la mobilite du reseau et du rumen due a piperoxan and phentolamine (15-18). seen at 0.5 mg/kg yohimbine, and la xylazine. Linjection de domperi- In these studies, yohimbine was found yohimbine at 0.2 mg/kg was less done, un antagoniste des recepteurs de to be the most effective agent for effective than tolazoline at 0.5 mg/kg. la dopamine, et celle de naloxone, un antagonism of the actions of xylazine. An adrenoceptor antagonist showing antagoniste des recepteurs d'opiate, ne In cattle, however, yohimbine is a,-blocking activity, prazosin, did not reussirent pas non plus a empecher ineffective in antagonizing xylazine- prevent the inhibition of reticulorumi- l'inhibition de la motilite du reseau et induced sedation (1), although tolazo- nal motility by xylazine. The xylazine- du rumen due a la xylazine. Les line antagonizes xylazine-induced induced reticuloruminal amotility was resultats de cette experience sous- central nervous system (CNS) depres- also not prevented by either a entendent que la xylazine inhibe la sion (2,19). As yohimbine is the most dopamine receptor antagonist, motilite du reseau et du rumen, chez les effective agent for blocking a2- domperidone, or an opiate receptor bovins, en activant les recepteurs adrenoceptors (16,18), its inability to antagonist, naloxone. These results adrenergiques a2; ils demontrent aussi antagonize the xylazine-induced seda- suggest that xylazine inhibits bovine la possibilite d'utiliser la tolazoline tion focuses attention on the receptive reticuloruminal motility through its comme antagoniste specifique de la mechanism of xylazine actions in the activation of a2-adrenoceptors, and xylazine, au cours d'etudes relatives a bovine CNS. It has been shown that show that tolazoline can be used as a l'influence des recepteurs adrener- xylazine-induced inhibition of reticu- specifilc antagonist of xylazine in giques sur la motilite du reseau et du lar motility in sheep is an effect studies of the a-adrenergic influence rumen, chez les bovins. resulting from the central activity of on reticuloruminal motility in cattle. xylazine (10,20), and so it seems of interest to examine whether the INTRODUCTION xylazine-induced reticuloruminal RESUME amotility in cattle is mediated by a2- Xylazine hydrochloride is widely adrenoceptors. L'injection intraveineuse d'une dose used in veterinary medicine as a Several attempts have been made to standard de 0,05 mg/kg de xylazine sedative, analgesic and muscle relaxant reverse the reticuloruminal amotility in inhiba la motilite du reseau et du agent. In particular, cattle are highly cattle induced by xylazine (1-3). As a rumen, chez des bovins. L'injection sensitive to xylazine. It is also known result, the xylazine-induced ruminal prealable d'antagonistes des recep- that this agent inhibits reticuloruminal amotility was reported to be reversed teurs adrenergiques, capables d'inhi- motility in cattle (1-3). by tolazoline (2,3) and yohimbine (1). *Department of Veterinary Surgery, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada-shi, Aomori 034, Japan. Submitted November 20, 1987. Can J Vet Res 1988; 52: 411-415 41 The xylazine-induced reticular amotil- TABLE I. Effects of a-Adrenoceptor, Dopamine and Opiate Receptor Blocking Agents on the ity was reported to be reversed by tola- Xylazine-induced Inhibition of Ruminal Motility in Cattle zoline (3). More recently, Ruckebusch Dose Number Duration of Ruminal Amotility and Allal (21) reported that the inhibi- Pretreatmenta (mg/kg) of Cows (Mean ± SD, Minutes) tion of bovine reticuloruminal contrac- None (Control) 5 48.0 ± 12.5 tions induced by xylazine was reversed Tolazoline 0.5 6 17.5 ± 10.4b by yohimbine and tolazoline. However, Yohimbine 0.2 5 29.0 ± 2.2c the receptor mechanism of the xyla- 0.5 6 37.5 12.5 reticuloruminal amotility Prazosin 0.5 5 54.0 ± 17.1 zine-induced Domperidone 0.5 5 69.0 ± 22.7 in cattle has not been well elucidated. Naloxone 0.1 5 51.0 ± 13.4 The present study was conducted to aPotential antagonists were injected intravenously ten minutes before the intravenous injection of determine whether xylazine-induced xylazine (0.05 mg/kg) inhibition ofreticuloruminal motility in bp < 0.01, cp < 0.05, when compared to the control group, that received xylazine only cattle is mediated by a2-adrenoceptors and whether this effect involves other receptor types. scopy. X-ray exposure was performed tolazoline hydrochloride (Imidalin®, continuously for 3 min with a horizon- 2% solution; Yamanouchi Pharma- MATERIALS AND METHODS tal X-ray beam, at 200 kVP and 4 mAs, ceutical Co. Ltd., Japan); and domperi- with an anode distance of 80 cm. The done (Nauzelin®, 0.2% solution; ANIMALS frequency of biphasic contractions of Kyowa Hakko Ind. Co. Ltd., Japan). Eleven nonlactating cows, ten the reticulum per 3 min was recorded Xylazine, tolazoline and domperidone Holsteins and one Jersey (4 to 11 years prior to drug administration, and then were used as the undiluted 2%, 2% and of age), weighing from 408 to 611 kg at 5, 15, 30, 45, 60, 75, 90, 105 and 120 0.2% solutions, respectively. Yohim- (mean 545 kg ± 63 SD), were used in min after the xylazine injection. The bine, naloxone and prazosin were this study. They were housed indoors at duration of reticular amotility (fre- dissolved in distilled water. All dosages night and kept outdoors during the day, quency of biphasic contractions, 0 per 3 were calculated on the basis of the drug and given a commercial cattle concen- min) was determined. base weight. trate, hay and water ad libitum. The Ruminal motility was measured by a animals were randomly used for each stethoscopic method. A stethoscope STATISTICAL ANALYSIS experiment. The same animal was not was attached to the left side of the The data were subjected to analysis used repeatedly more than five times. abdomen. The ruminal sounds were of variance and Student's t-test The experiments were performed in a monitored in the intervals between the (p < 0.05) (22). large animal X-ray room with the X-ray exposures. After the xylazine temperature controlled at 20 ± 10 C. injection, the duration of ruminal Food and water were withheld during amotility (no ruminal sounds per 3 min) RESULTS the was determined. experiments. EFFECTS OF a2-ADRENOCEPTOR, EXPERIMENTAL GROUPS MEASUREMENT OF SEDATION DOPAMINE AND OPIATE RECEPTOR The animals were used in seven Additionally, the duration of seda- BLOCKING AGENTS ON THE XYLAZINE- groups of five to six cows each. The tion was measured in this study. The INDUCED INHIBITION OF RUMINAL groups comprised nonpretreated con- intravenous injection of xylazine MOTILITY trols and cows pretreated with yohim- (0.05 mg/ kg) induced CNS depression, The results are summarized in Table bine at 0.2 mg/kg bodyweight which was characterized by transient I. The ruminal sound frequency was (0.04 mL/ kg) and 0.5 mg/kg body- recumbency, knuckling of the fetlock approximately 1 per min prior to drug weight (0.07 mL/kg), tolazoline at joints, head-down posture, open-limbs administration. In the control cows, 5 0.5 mg/kg (0.025 mL/kg), prazosin at and unsteady walking. The duration of min after the intravenous injection of 0.5 mg/ kg (0.05 mL/ kg), domperidone xylazine-induced sedation was taken as xylazine (0.05 mg/kg bodyweight) at 0.5 mg/kg (0.25 mL/kg) and nalox- the time between initial knuckling of ruminal sounds had disappeared. The one at 0.1 mg/ kg (0.01 mL/ kg). Cows the fetlock joints and head-down mean duration of ruminal amotility in each group received a single intraven- posture and the time of recovery from was 48 min. Pretreatment with an a2- ous injection of xylazine at the dosage all effects described above. blocker, tolazoline (0.5 mg/ kg), greatly of 0.05 mg/kg bodyweight (0.0025 reduced the duration of ruminal mL/ kg). All the potential antagonists DRUGS USED amotility induced by xylazine. A were injected intravenously 10 min The drugs used and their sources second a2-blocker, yohimbine, at before the xylazine administration. were as follows: xylazine hydrochloride 0.5 mg/kg did not significantly reduce (Celactal®, 2% solution; Bayer Japan); the duration of xylazine-induced MEASUREMENTS OF RUMINAL yohimbine hydrochloride and nalox- rumen amotility.
Load more

Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M
    - + ! ,' Br. J. Pharmac. (1978), 64, 293-300. F'(O t.,," e reab- ,ellular PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC _-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM 1978) G.M. Departmentof Pharmacology,Allen and HzmburysResearchLimited, Ware, Hertfordshire,SG12 ODJ I The presynaptic ct-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to at-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ! ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch i response; the maximum inhibition obtained was 80 to 95_o of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 lag/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
    [Show full text]
  • Drug Code List Version 11.2 Revised 9/11/17 List Will Be Updated Routinely
    Drug Code List Version 11.2 Revised 9/11/17 List will be updated routinely Disclaimer: For drug codes that require an NDC, coverage depends on the drug NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service. Note: Physician/Facility-administered medications are reimbursed using the Centers for Medicare and Medicaid Services (CMS) Part B Drug pricing file found on the CMS website--www.cms.hhs.gov. In the absence of a fee, pricing may reflect the methodolgy used for retail pharmacies. Highlights represent updated material for each specific revision of the Drug Code List. Code Description Brand Name NDC NDC unit Category Service AC CAH P NP MW MH HS PO OPH HI IDT DC Special Instructions Requir of Limits OP OP F ed measure 90281 human ig, im Gamastan Yes ML Antisera NONE X X X X Closed 3/31/13. 90283 human ig, iv Gamimune, Yes ML Antisera NONE X X X X Closed 3/31/13. Cost invoice required with claim. Restricted to ICD-9 diagnoses codes 204.10 - 204.12, Flebogamma, 279.02, 279.04, 279.06, 279.12, 287.31, and 446.1, and must be included on claim form, effective 10/1/09. Gammagard 90287 botulinum antitoxin N/A Antisera Not Covered 90288 botulism ig, iv No ML NONE X X X X Requires documentation and medical review 90291 cmv ig, iv Cytogam Yes ML Antisera NONE X X X X Closed 3/31/13. 90296 diphtheria antitoxin No ML NONE X X X X 90371 hep b ig, im Bayhep B, Yes ML Antisera NONE X X X X Closed 3/31/13.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Selection of Vasodilator Therapy for Severe Raynaud's Phenomenon by Sequential Arterial Infusion
    Ann Rheum Dis: first published as 10.1136/ard.44.3.151 on 1 March 1985. Downloaded from Annals of the Rheumatic Diseases, 1985; 44, 151-154 Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion I JON RUSSELL AND RICHARD A WALSH From the Department of Medicine, Divisions of Clinical Immunology and Cardiology, the University of Texas Health Science Center at San Antonio, USA. SUMMARY Two young adults with impending gangrene due to persistent Raynaud's vasospasm were studied by sequential intra-arterial (IA) infusion of three vasodilatory drugs while arterial pressure and plethysmographic digital pulse volume were continuously monitored. The results of the IA infusion accurately predicted relief from vasospastic symptoms by oral drugs of the same class. This method may be useful in selecting the most effective vasodilator for patients with severe vasospasm. Key words: vasodilatation, tolazoline, hydralazine, diltiazem, phenoxybenzamine. Raynaud's phenomenon may occur as an isolated (PVR-4, Life Sciences Incorporated, Greenwich, copyright. problem or as one manifestation of a major clinical CT). This semisegmental plethysmograph uses an syndrome. The management of infrequent vasospas- air-containing cuff round the proximal or distal tic episodes can be as simple as avoidance of cold, phalanx to plot pulsations as wave fortns on a strip wearing of gloves, or windmilling the affected arm recorder.5 By inflating a second cuff round the to override the increased vascular tone.' For pa- proximal phalanx the pressure required to obliterate tients with very frequent or persistent attacks a pulsation at the distal phalanx was determined, and variety of chemotherapeutic remedies have been it was defined as the finger systolic pressure.
    [Show full text]
  • Redalyc.Effcts of Cassia Podocarpa Leaves Extracts on the Rat Ileum And
    Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas ISSN: 0717-7917 [email protected] Universidad de Santiago de Chile Chile Akomolafe, R.O.; Adeoshun, I.O.; Elujoba, A. A.; Iwalewa, E.O.; Ayoka, A.O. Effcts of cassia podocarpa leaves extracts on the rat ileum and colon (in vitro) Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas, vol. 3, núm. 3, mayo, 2004, pp. 52-57 Universidad de Santiago de Chile Santiago, Chile Available in: http://www.redalyc.org/articulo.oa?id=85630303 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative BLACPMA Vol. 3 Nº 3 Mayo 2004 52 ARTICULOS stimulated by the extract. With this results therefore, C. podocarpa leaves could be EFFCTS OF CASSIA PODOCARPA substituted for C. acutifolia leaves as LEAVES EXTRACTS ON THE RAT vegetable laxative. ILEUM AND COLON (IN VITRO) KEY WORDS: Motility, Anthraquinone, Allosteric activation. 2* 1 R.O. AKOMOLAFE , I.O. ADEOSHUN , 3 4 A.A. ELUJOBA , E.O. IWALEWA RESUMEN: La etnofarmacología y los AND informes científicos indican el uso hojas de C. 1 A.O. AYOKA podocarpa como purgante. Este estudio intenta encontrar el efecto in vitro de su Recibido: 16 May 2003 infusión ácuosa (ACPL) y los methanolic Recibido corregido: 1 September 2003 (MCPL) en el intestines de ratas, usando Aceptado: 30 November 2003 hojas de C. acutifolia (ACAL y MCAL) como la norma de la referencia.
    [Show full text]
  • Xylazine Tolazoline
    United States Department of Agriculture Agricultural Marketing Service | National Organic Program Document Cover Sheet https://www.ams.usda.gov/rules-regulations/organic/national-list/petitioned Document Type: ☐ National List Petition or Petition Update A petition is a request to amend the USDA National Organic Program’s National List of Allowed and Prohibited Substances (National List). Any person may submit a petition to have a substance evaluated by the National Organic Standards Board (7 CFR 205.607(a)). Guidelines for submitting a petition are available in the NOP Handbook as NOP 3011, National List Petition Guidelines. Petitions are posted for the public on the NOP website for Petitioned Substances. ☒ Technical Report A technical report is developed in response to a petition to amend the National List. Reports are also developed to assist in the review of substances that are already on the National List. Technical reports are completed by third-party contractors and are available to the public on the NOP website for Petitioned Substances. Contractor names and dates completed are available in the report. Xylazine/Tolazoline Livestock 1 2 Identification of Petitioned Substance 3 4 Chemical Names: 43 5 Xylazine 44 Trade Names: 6 Xylazine 45 Xylazine 7 Xylazine Hydrochloride 46 AnaSed® LA 8 Xylazine Monohydrochloride 47 Rompun® 9 N-(2,6-Diphenylmethyl)-5,6-dihydro-4H-1,3- 48 TranquiVed Injection 10 thiazin-2-amine 49 X-Ject SA 11 N-(2,6-Diphenylmethyl)-5,6-dihydro-4H-1,3- 50 XylaMed™Celactal 12 thiazin-2-amine hydrochloride 51 13 52
    [Show full text]
  • Drugs, Poisons and Controlled Substances Act 1981
    1834 ANNO TRICESIMO ELIZABETHAE SECUNDAE REGINAE VICTORIA Drugs, Poisons and Controlled Substances Act 1981 No. 9719 An Act to re-enact with Amendments the Law relating to Drugs, Poisons and Controlled Substances, to amend the Health Act 1958 and the Crimes Act 1958 and for other purposes. [Assented to 12 January 1982] BE IT ENACTED by the Queen's Most Excellent Majesty by and with the advice and consent of the Legislative Council and the Legislative Assembly of Victoria in this present ParUament assembled and by the authority of the same as follows (that is to say): Short tiUe. 1. (1) This Act may be cited as the Drugs, Poisons and Controlled Substances y4cM981. Commenco- (2) The several provisions of this Act shall come into operation ment. on a day or on the respective days to be fixed by proclamation or successive proclamations of the Governor in Council published in the Government Gazette. Arrangement (3) This Act is divided into Parts and Divisions as follows: of Act. Part I.—Introductory and Transitional ss. 2-11. Part II.—Poisons and Controlled Substances ss. 12-55. Division 1—Classification s. 12. Division 2—Authorized Persons ss. 13-14. Division 1981 Drugs, Poisons and Controlled Substances No. 9719 2335 Division 3—Poisons Advisory Committee ss. 15-18. Division 4—Licensed Persons s. 19. Division 5—Special Poisons s. 20. Division 6—Industrial, Educational and Laboratory Permits s. 21. Division 7—Issue of Licences and Permits s. 22. Division 8—Manufacture and Sale of Poisons or . Controlled Substances ss. 23-30. Division 9—Trade or Proprietary Poisons s.
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • PRESYNAPTIC O-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY in the GUINEA-PIG ILEUM
    Br. J. Pharmac. (1978), 64, 293-300. PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC o-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM G.M. DREW Department of Pharmacology, Allen and Hanburys Research Limited, Ware, Hertfordshire, SG12 ODJ 1 The presynaptic ax-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to a-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch response; the maximum inhibition obtained was 80 to 95% of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 jg/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
    [Show full text]